Inpatient Management of Heart Failure Mini-Lecture.

Slides:



Advertisements
Similar presentations
Long Distance Titration of Heart Failure Medications by Telephone Calls Anne E. Steckler, RN, Heba Wassif, MD, Kalkidan Bishu, MD, Gardar Sigurdsson, MD,
Advertisements

Evaluation and Management of Acute Decompensated Heart Failure
Chapter 20 Heart Failure.
Diuretic Strategies in Patients with Acute Decompensated Heart Failure Diuretic Optimization Strategies Evaluation (DOSE) trial.
HEART FAILURE: ANSWERS YOU NEVER GET TO QUESTIONS YOU ALWAYS ASK BART COX, M.D.FACC DIRECTOR, ADVANCED HEART FAILURE PROGRAM ASSOCIATE PROFESSOR OF MEDICINE.
Cardiac Drugs in Heart Failure Patients Zoulikha Zair 28 th May 2013 N.B. some drugs overlap with treatment of hypertension….bonus revision wise!!!!
Heart Failure. Objectives Describe congestive heart failure Explain the pathophysiology of congestive heart failure Describe nursing interventions in.
 Heart failure is a complex clinical syndrome Can result from:  structural or functional cardiac disorder  impairs the ability of the ventricle to.
Congestive heart failure guideline. Functional classification( NYHA) Class IV: symptoms at rest Class III: symptoms on less-than-ordinary exertion Class.
Heart Failure Management Focus on Primary Care Practice.
Congestive heart failure
1 Heart Failure William Chavey, MD, MS Associate Professor Department of Family Medicine University of Michigan.
Corlanor® - Ivabradine
1 Cardiac Pathophysiology Part B. 2 Heart Failure The heart as a pump is insufficient to meet the metabolic requirements of tissues. Can be due to: –
Congestive heart failure
Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.
Case Studies in Advanced Monitoring: OptiVol
Dr. Jon Salisbury Visiting Physician Services A Member of VNA Health Group No Disclosures May 14, :40PM – 2:00PM ©AAHCM.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Pharmacological Therapy of Heart Failure: Case presentations Steven W. Harris MHS, PA-C.
Heart Failure, HF CHF develops when plasma volume increases and fluid accumulates in the lungs, abdominal organs (liver especially), and peripheral tissues.
Heart Failure Karen Ruffin RN, MSN Ed..
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
Drugs for CCF Heart failure is the progressive inability of the heart to supply adequate blood flow to vital organs. It is classically accompanied by significant.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
TREATMENT OF ACUTE DECOMPENSATED HEART FAILURE
Supporting Patients with CHF Care Transformation Collaborative of R.I. MAUREEN CLAFLIN, MSN, RN. NCM UNIVERSITY MEDICINE GOVERNOR STREET PRIMARY CARE CENTER.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
Causes Myocardial dysfunction eg IHD, CM Volume overload eg AR, MR Obstruction eg AS, HCM Diastolic dysfunction eg Constriction Mechanical problems eg.
Treatment of Heart Failure Claire Hunter, MD. Treatment of Heart Failure Goals Improve quality of life Prolong life Ejection fraction most important.
CARDIOVASCULAR CARE of the OUTPATIENT Diane M. Enzweiler, MSN, ANP-BC St. Elizabeth Physicians: Heart and Vascular.
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.
Compliance with clinical practice guidelines for the treatment and optimization of therapy in heart failure patients in outpatient medicine clinics MaryAnn.
Chronic Heart Failure Clinical case scenarios for primary care Educational Resource Implementing NICE guidance August 2010 NICE clinical guideline 108.
Congestive Heart Failure ADOPTED FROM: Jarrod Eddy, PGY2 Internal Medicine Sub-I Lecture Series ADOPTED FROM: Jarrod Eddy, PGY2 Internal Medicine Sub-I.
Nursing and heart failure
Bipyridines :(Amrinone,Milrinone ) only available in parenteral form. Half-life 3-6hrs. Excreted in urine.
Inferior/Right Ventricular Infarction CLINICAL PRESENTATION AND TREATMENT Lady Minto Hospital Emergency Rounds February 2015 Prepared by Shane Barclay.
NYU Medical Grand Rounds Clinical Vignette Justin Simmons, M.D. Class of /27/2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.
Heart Failure. Background to Congestive Heart Failure Normal cardiac output needed to adequately perfuse peripheral organs – Provide O 2, nutrients, etc.
Heart Failure: ACC Guidelines for Dx and Management Steven W. Harris MHS PAC.
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
HEART FAILURE Jamil Mayet Consultant Cardiologist.
CURRENT APPROACH TO THE TREATMENT OF CONGESTIVE HEART FAILURE.
– Dr. J. Satish Kumar, MD, Department of Basic & Medical Sciences, AUST General Medicine CVS Name:________________________________________ Congestive Heart.
Internal Medicine Workshop Series Laos September /October 2009
Heart Failure: medication Types of Heart Failure Systolic (or squeezing) heart failure –Decreased pumping function of the heart, which results in fluid.
Exercise Management Chronic Heart Failure Chapter 12.
Management of Heart Failure Dr. M.Kheir Mulki. What is the definition of Heart Failure ?
Heart Failure J. Lynn Davis, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April 25, 2015.
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
The Cardiac Side of the Cardio-Renal Dilemma
HF diagnosis: audit of NTproBNP uptake and outcomes across Sheffield An update on diagnosis and management of HF Dr Abdallah Al-Mohammad, MD, FRCP(Edin),
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, Marvin A. Konstam, G. Michael.
Heart Failure NURS 241 Chapter 35 (p.797).
Heart Failure The inability of the heart to pump sufficient blood to meet the needs of the tissues for oxygen and nutrients. A syndrome characterized.
Congestive heart failure
Jeannine Costigan RN(EC) Nurse Practitioner Heart Function Clinic
Clyde W. Yancy et al. JACC 2017;70:
Expert Insights on Complex Clinical Cases of Edema
Jeannine Costigan RN(EC) Nurse Practitioner Heart Function Clinic
Jeannine Costigan RN(EC) Nurse Practitioner Heart Function Clinic
What is the relative risk reduction of ACEi’s/beta blockers for HFrEF?
Inferior/Right Ventricular Infarction
Khalid AlHabib Professor of Cardiac Sciences Cardiology Consultant
Presentation transcript:

Inpatient Management of Heart Failure Mini-Lecture

Objectives -Learn how to assess jugular venous distension (JVD) to aid in assessment of acute decompensated heart failure (ADHF) -Interpret BNP in the setting of ADHF -Understand treatment options based on clinical presentation -Perform effective inpatient monitoring -Conduct a successful discharge -Know the natural history of HF

Jugular Venous Distension JVD: Indication of volume overload, especially on the right side of the heart

BNP –<100 high negative predictive value –>400 consistent with HF –A.fib, chronic HF, pulmonary HTN, renal failure  higher at baseline, so use higher cut- off for dx of ADHF –Lower in obese people at baseline, so use lower cut-off for dx of ADHF

Treatment: Who needs What? WARM AND DRY Compensated Optimize oral therapy Outpatient COLD AND DRY Low Flow State Inotropes, vasodilators, ?IABP ICU COLD AND WET Decompensated Diuretics, vasodilators, inotropes ICU WARM AND WET Congested Diuretics ED or Inpatient Adapted from Nohria,J Cardiac Failure 2000;6:64 CARDIAC OUTPUT PULMONARY CAPILLARY WEDGE PRESSURE ICU Floor Home

Treatment: General Medicine Floor Loop Diuretics –Administration: IV mg two or more times per day –Comments: Monitor for excess diuresis, electrolyte abnormalities. For those already on home lasix, give their usual oral dose in IV form, which is essentially a doubling of their home dose. ACE-I –Mechanism: Acute reduction in preload and afterload –Administration: Orally or IV. Escalate dose as BP tolerates. –Comments: Continue/start even in mild to moderate renal failure without hyperkalemia as renal failure will likely resolve with increased perfusion. Positive Pressure Ventilation –Mechanism: Alveolar recruitment and reducing preload and afterload. –Administration: CPAP or BIPAP –Comments: Hypoxic patients. Beta-blockers –Continue for patients already taking BB UNLESS hypotension, hypoperfusion. –For patients not taking BB, withhold during early management, but initiate prior to discharge. Aldosterone antagonists –Continue for patients already taking aldosterone antagonist. –For patients not taking an aldosterone antagonist who have an indication for therapy, initiate prior to discharge.

Treatment: ICU Nitrates –Mechanism: Acute decrease in filling pressure. At higher doses, arteriodilator. –Administration: as drip in the ICU –Comments: Oral and patch possible, but less efficacious and more difficult to titrate. Inotropes –Mechanism: Stimulation of the B1 adreoceptors of the heart, increasing contractility and cardiac output –Administration: as drip in ICU –Comments: Contraindicated in ischemic heart disease b/c increases oxygen demand. Use cautiously with a.fib.

Inpatient Monitoring At least daily –Weight –Intake and output –Symptoms and exam –Renal function and electrolytes More frequently –Vital signs

Disposition Planning Your patient is ready for dispo when… –Near optimal volume status achieved –Transition from IV to oral medications for at least 24 hours

Disposition: Case Example Mr. Jones: 64 yo AA male admitted for ADHF secondary to dietary noncompliance. Medical history significant for HF due to ischemic heart disease and CKD 2/2 chronic hypertension. He is ready for discharge and back to his baseline—SOB with minimal activity, but not at rest. His home medication regimen includes – carvedilol 12.5 mg BID – lisinopril 40 mg daily – ASA 81 mg daily – lasix 40 mg BID BP 115/70, HR 65, dry weight 200 lbs. PE: trace edema, JVD of 9 cm, and lungs are CTAB. Labs: BUN of 17, Creatinine 1.8, and Potassium of 4.6. Discharge EF is 35%. Appointment to see his PCP in three days.

Disposition Planning: New Guidelines Left ventricular Ejection Fraction Beta-blocker therapy ACE or ARB Postdischarge appointment Symptom and activity assessment and advice on symptom management. Patient self-care education. Counseling about implantable cardioverter defibrillators (ICDs)

Disposition: Lingering Questions Who needs hydralazine and nitrates? Who needs spironolactone? Who needs an ICD? Who needs a pacemaker?

Disposition: Case Example Mr. Jones: 64 yo AA male admitted for ADHF secondary to dietary noncompliance. Medical history significant for HF due to ischemic heart disease and CKD 2/2 chronic hypertension. He is ready for discharge and back to his baseline—SOB with minimal activity, but not at rest. His home medication regimen includes – carvedilol 12.5 mg BID – lisinopril 40 mg daily – ASA 81 mg daily – lasix 40 mg BID Labs: BUN of 17, Creatinine 1.8, and Potassium of 4.6. Discharge EF is 35%. Appointment to see his PCP in three days. 1.Is Mr. Jones on appropriate medications? Do any medications need to be added to Mr. Jones’ regimen? 2.What important discharge guidelines have been met already? 3.What important discharge guidelines need to be met before he is ready to go home?

Prognosis

Final Clinical Pearls Use physical exam (JVD) and ancillary tests(BNP) to assess ADHF Tailor treatment based on clinical presentation. Follow guidelines when planning for disposition HF is a waxing and waning disease that is ultimately fatal

References -American College of Cardiology Foundation (ACCF) American Heart Association (AHA) Physician Consortium for Performance Improvement® (PCPITM) Heart Failure Performance Measurement Set Jain P, et al; Am Heart J 2003; 145: S3-17 -Allen LA, O’Conner CM; CMAJ 2007: 176 (6): Treatment of acute decompensated heart failure: Components of therapy in UpToDate. Wilson S Colucci, MD. Literature review current through: Apr | This topic last updated: Jan 26, Seo,R Kam,L F Hsu Treatment of Heart Failure – Role of Biventricular Pacing for Heart Failure. SingaporeMedJ2003Vol44(3):